Citadel Advisors’s TuHURA Biosciences HURA Stock Holding History

Citadel Advisors’s Portfolio HURA Stock Details HURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-142	Closed	-$127K	–	14758
2021 Q4	$127K	Buy	+142	New	+$192K	﹤0.01%	12471
2021 Q3	–	Sell	-26	Closed	-$104K	–	14814
2021 Q2	$104K	Sell	26 -18	-41%	-$51.7K	﹤0.01%	12891
2021 Q1	$134K	Buy	+44	New	+$149K	﹤0.01%	12178
2020 Q3	–	Sell	-13	Closed	-$16K	–	10864
2020 Q2	$16K	Buy	+13	New	+$16.6K	﹤0.01%	9586
2019 Q4	–	Sell	-19	Closed	-$18K	–	9883
2019 Q3	$18K	Buy	+19	New	+$35.7K	﹤0.01%	8966
2019 Q2	–	Sell	-3	Closed	-$22K	–	9976
2019 Q1	$22K	Hold	3	–	–	﹤0.01%	9049
2018 Q4	$21K	Buy	3 +1	+50%	+$9.7K	﹤0.01%	8738
2018 Q3	$20K	Buy	2 +1	+100%	+$10.8K	﹤0.01%	9010
2018 Q2	$15K	Hold	1	–	–	﹤0.01%	8693
2018 Q1	$14K	Buy	+1	New	+$21.9K	﹤0.01%	8159

Other funds holding HURA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors's HURA Position: Q1 2022 in Review

Citadel Advisors sold out of TuHURA Biosciences (HURA) in Q1 2022, closing a stake of 142 shares — an estimated $127K sold.

Citadel Advisors first reported a position in HURA in Q1 2018 and held it in 10 quarters. The position peaked at $134K in Q1 2021. 22 funds tracked by Wall St. Rank hold HURA as of Q1 2022.

Citadel Advisors reported no remaining TuHURA Biosciences position as of Q1 2022 after selling out during the quarter.
Citadel Advisors sold 142 TuHURA Biosciences shares in Q1 2022, an estimated $127K.
Citadel Advisors first reported a position in TuHURA Biosciences in Q1 2018 and held it in 10 quarters.
Citadel Advisors's TuHURA Biosciences position peaked at $134K in Q1 2021.
22 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.